Yazar "Yildiz, Yasar" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
    (Lippincott Williams & Wilkins, 2022) Ozdemir, Ozlem; Zengel, Baha; Yildiz, Yasar; Uluc, Basak Oyan; Cabuk, Devrim; Ozden, Ercan; Salim, Derya Kivrak
    In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data collected from 32 centers. Our study was multicentric, and a total of 364 patients were included. The median age of the patients was 49 years (18-85 years). Two hundred fifteen (60%) of the cases were hormone receptor/HER2+ positive(ER+ or PR+, or both), and 149 (40%) of them were HER2-rich (ER and PR negative). The number of complete responses was 124 (54%) in the docetaxel+trastuzumab+pertuzumab arm and 102 (45%) in the paclitaxel+trastuzumab+pertuzumab arm, and there was no difference between the groups in terms of complete response. In 226 (62%) patients with complete response, a significant correlation was found with DCIS, tumor focality, removed lymph node, and ER status P < 0.05. Anemia, nausea, vomiting, myalgia, alopecia, and mucosal inflammation were significantly higher in the docetaxel arm, P < 0.05. In our study, no statistical difference was found between the before-after echocardiography values. DCIS positivity in biopsy before neoadjuvant chemotherapy, tumor focality; the number of lymph nodes removed and ER status were found to be associated with pCR. In conclusion, we think that studies evaluating pCR-related clinicopathological variables and radiological imaging features will play a critical role in the development of nonsurgical treatment approaches.
  • Küçük Resim
    Öğe
    Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study
    (2020) Taskaynatan, Halil; Kucukzeybek, Yuksel; Yildiz, Yasar; Salman, Tarik; Oflazoglu, Utku; Varol, Umut; Alacacioglu, Ahmet; Saray, Seray; Ozdemir, Ozlem; Tarhan, Mustafa Oktay
    Aim: Oral etoposide dosage is roughly 50-100 mg/m2 on days 1 to 21 every 28 days. However, dosage of 50 mg/day oral etoposide for five days a week is not well published. The present study, aimed to evaluate the efficacy and toxicity profile of low dose oral etoposide regimen (50 mg/day on days 1 to 5 every week) in platinum-resistant epithelial ovarian cancer (EOC).Material and Methods: This study retrospectively evaluates patients with pathologically confirmed platinum-resistant EOC who were unable to tolerate the standard oral etoposide regimen and were on low dose (d1-5/7) oral etoposide regimen in third line or beyond within the period between 2006 and 2014.Results: The overall response rate among 33 EOC patients was 15.1% while clinical benefit rate was 42.4% (stable disease in 27.3% and partial response in 15.1%). Median progression-free survival was 4 months (95% confidence interval [CI], 2.8–5.1 months) and median overall survival was 12 months (95% CI, 8.8–15.1 months). Conclusion: We concluded that low dose oral etoposide (50 mg/day, on days 1 to 5 every week) was effective and well tolerated for platinum-resistant EOC.
  • Küçük Resim
    Öğe
    Prognostic role of pretreatment de ritis and neutrophil to lymphocyte ratio in neuroendocrine carcinoma patients (Izmir oncology group study)
    (2020) Varol, Umut; Oflazoglu, Utku; Uzum, Yusuf; Yildiz, Yasar; Salman, Tarik; Taskaynatan, Halil
    Aim: Neutrophil/lymphocyte ratio (NLR) and AST/ALT ratio (De Ritis) were found to be prognostic in several cancers. So, our aim was to investigate the prognostic importance of these parameters and clinicopathological characteristics in patients with neuroendocrine carcinoma (NEC). Material and Methods: We retrospectively reviewed 101 NEC patients diagnosed in the last decade. The values of NLR and De Ritis were assessed at the time of diagnosis and their cut-off values were determined as 5 and 1.04 by receiver operating characteristics analysis. The prognostic role of high or low NLR and De Ritis according to these cut-off values and patient or tumor characteristics on clinical outcome was evaluated. Results: Among 101 patients, 77 were metastatic and 24 were early or locally advanced stage. Almost all patients were death at the time of data analysis (n:90). Twelve patients were treated with adjuvant chemotherapy or radiotherapy while 41 metastatic patients had received first-line chemotherapy. Median overall survival (OS) and progression free survival (PFS) was 7 months and 5 months in NLR low group and 6 months and 4 months in NLR high group (p:0.043, p:0.354), respectively. Median OS was 9 months in De Ritis low group and 5 months in De Ritis high group (p:0.004) while median PFS was 5 and 4 months in De Ritis low and high group of patients (p:0.077). Conclusion: Low De Ritis showed a strong and low NLR showed a weaker association with improved prognosis in patients with NEC.